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Abstract
Background: Dimethyl sulfoxide (DMSO) is an amphipathic molecule that displays a diversity of antitumor activities.
Previous studies have demonstrated that DMSO can modulate AP-1 activity and lead to cell cycle arrest at the G1 phase.
HLJ1 is a newly identified tumor and invasion suppressor that inhibits tumorigenesis and cancer metastasis. Its
transcriptional activity is regulated by the transcription factor AP-1. However, the effects of DMSO on HLJ1 are still
unknown. In the present study, we investigate the antitumor effects of DMSO through HLJ1 induction and demonstrate the
mechanisms involved.
Methods and Findings: Low-HLJ1-expressing highly invasive CL1–5 lung adenocarcinoma cells were treated with various
concentrations of DMSO. We found that DMSO can significantly inhibit cancer cell invasion, migration, proliferation, and
colony formation capabilities through upregulation of HLJ1 in a concentration-dependent manner, whereas ethanol has no
effect. In addition, the HLJ1 promoter and enhancer reporter assay revealed that DMSO transcriptionally upregulates HLJ1
expression through an AP-1 site within the HLJ1 enhancer. The AP-1 subfamily members JunD and JunB were significantly
upregulated by DMSO in a concentration-dependent manner. Furthermore, pretreatment with DMSO led to a significant
increase in the percentage of UV-induced apoptotic cells.
Conclusions: Our results suggest that DMSO may be an important stimulator of the tumor suppressor protein HLJ1 through
AP-1 activation in highly invasive lung adenocarcinoma cells. Targeted induction of HLJ1 represents a promising approach
for cancer therapy, which also implied that DMSO may serve as a potential lead compound or coordinated ligand for the
development of novel anticancer drugs.
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Introduction
Dimethyl sulfoxide (DMSO; (CH3)2SO) is an amphipathic
molecule that has a highly polar domain and two apolar methyl
groups, making it soluble in both aqueous and organic media [1].
Although its biological effects have not been clearly defined, it is
used extensively in a variety of fields. It is commonly used as a very
efficient solvent for water-insoluble compounds in biological
studies and a cryoprotectant of cultured cells [2]. In addition, it
is also popularly used as a vehicle for drug therapy for various
diseases, including dermatological disorders [3], amyloidosis [4],
gastrointestinal diseases [5], [6], traumatic brain edema [7],
musculoskeletal disorders [8], pulmonary adenocarcinoma [9],
rheumatologic diseases [10], and schizophrenia [11]. In particular,
DMSO used in the treatment of interstitial cystitis has been
approved by the United States Food and Drug Administration
[12]. DMSO also had been used for treatment of leukemia for
several years as it induces cellular differentiation, causing leukemia
cells to lose their proliferative properties [13], [14]. Recent study
also demonstrated that DMSO might induce cardiomyogenesis of
P19CL6 embryonal carcinoma cells [15]. Furthermore, DMSO
has been found to arrest the cell cycle of lymphoid cell lines at the
G1 phase [16], [17], and it can effectively inhibit capillary tube
formation through MMP-2 suppression [18].
With its high relapse and low cure rates, lung cancer is the most
common cause of cancer mortality and incidence in the world
[19]. Adenocarcinoma is the predominant histologic subtype
of lung cancer in most countries, making up approximately 50%
of all lung cancers [20]. In a previous study, we screened a series of
human lung adenocarcinoma cell lines with varying invasion
capabilities by microarray and identified a panel of metastasis-
related genes including the human liver DnaJ-like protein (HLJ1,
also known as DNAJB4) [21]. We subsequently demonstrated that
HLJ1, a tumor suppressor in non-small cell lung cancer (NSCLC),
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growth, motility, invasion, tumorigenesis, and cell cycle pro-
gression. In addition, HLJ1 expression is correlated with reduced
cancer recurrence and prolonged survival of NSCLC patients
[22]. Furthermore, the endogenous transcriptional expression of
HLJ1 is upregulated via enhancer activator protein-1 (AP-1)
binding to its promoter Yin-Yang-1 (YY1) with the coactivator
p300 [23], [24]. Due to its tumor suppressor properties, HLJ1 is
a potential target for anticancer therapy [25]. Importantly, HLJ1
was reported to promote UV-induced apoptosis through JNK and
caspase-3 activation in NSCLC. Additionally, HLJ1 is a novel
substrate of caspase-3 and is degraded at a late stage of apoptosis
[26]. Therefore, clarifying the molecular mechanisms involved in
HLJ1 upregulation may be important for anticancer therapy.
Indeed, curcumin, an active component of the spice turmeric, has
been reported to inhibit lung cancer cell invasion and metastasis
through HLJ1 [27]. However, whether any other small molecules
or chemicals can effectively modulate HLJ1 expression is still
unknown.
Several studies have revealed that DMSO treatment can
modulate AP-1 activity. For instance, it is involved in the
suppression of ICAM-1 expression in a rat model of peritonitis
sepsis [28] and in the respiratory syncytial virus (RSV)-induced
production of IL-8 in A549 epithelial cells [29]. Because HLJ1 is
transcriptionally upregulated by AP-1, we hypothesized that HLJ1
expression may be regulated by DMSO. In this report, we
investigated the effect of DMSO on HLJ1 expression, the
mechanism of DMSO-induced HLJ1 expression and the antican-
cer effects of DMSO in human lung adenocarcinoma CL1–5 cells.
Moreover, we explored the effect of DMSO on apoptosis in CL1–
5 cells exposed to UV stress.
Methods
Cell Culture
The human lung adenocarcinoma cell lines CL1–5 (with low
HLJ1 expression, a gift from Dr. Cheng-Wen Wu) [30], NCI-
H1299 (ATCC CRL-5803) and A549 (ATCC CCL-185) cells
were maintained at 37uC in a humidified atmosphere of 5% CO2.
Cells were cultured in RPMI-1640 medium (Life Technologies,
Inc., Carlsbad, CA, USA) supplemented with 10% heat-inacti-
vated fetal bovine serum (FBS; Life Technologies, Inc.) and 1%
penicillin-streptomycin (Life Technologies, Inc.).
Cell Cytotoxicity Assay
CL1–5 cells were seeded onto 96-well plates and cultured for
48 h with various concentrations of DMSO (0, 0.1%, 1%, 2%,
5%, and 10% v/v) (Sigma, St Louis, MO, USA). After culturing
for various durations of time, cell viability was evaluated by the
thiazolyl blue tetrazolium bromide (MTT) assay (Promega,
Madison, WI, USA) using the multiwell scanning spectrophotom-
eter Victor 3 (Perkin-Elmer, Boston, MA, USA) with the
absorbance wavelength set at 570 nm.
Immunofluorescent Staining
Cells cultured on 12 mm glass cover-slips were fixed for 15 min
in PBS containing 4% paraformaldehyde and 2% sucrose and
then permeabilized in PBS containing 0.3% Triton X-100 for
2 min. Cover-slips were incubated with primary antibody against
F-actin at 4uC overnight followed by rhodamine-conjugated
second antibody (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA. USA). 49,6-diamidino-2-phenylindole (DAPI) was used as
a counter stain for cell nuclei, and the cells were mounted onto
slides and visualized by a confocal laser scanning microscope (Clsi;
Nikon).
Western Blot Analysis
Western blot analysis was used to examine the protein
expression levels of JunD, JunB, Fra-1, and HLJ1 before and
after DMSO treatment for 48 h. The detailed procedures were as
described previously (Wang et al., 2005). The primary antibodies
for JunD, JunB, Fra-1, and HLJ1 were purchased from Santa
Cruz Biotechnology, Inc. b-actin or a-tubulin was used as the
internal control for gel loading. The membranes were then washed
three times with TBST followed by incubation with horseradish
peroxidase (HRP)-conjugated secondary antibody (Santa Cruz
Biotechnology, Inc) and detection using an enhanced chemilumi-
nescence detection system (ECL, GE Healthcare, Piscataway, NJ,
USA).
Real-time Quantitative Reverse Transcription-PCR
The expression level of HLJ1 before and after DMSO treatment
was detected with real-time PCR on an ABI prism 7900 sequence
detection system (Applied Biosystems, Carlsbad, CA, USA). The
HLJ1 primers are as follows: forward primer QHLJ1-F, 59-
CCAGCAGACATTG- TTTTTATCATT-39; reverse primer
QHLJ1-R, 59-CCATCCAGTGTTGGTACATTAATT-39.
TATA-box binding protein (TBP) was used as the internal control
(GenBank X54993). The primers used for TBP mRNA are
described previously [31]. The relative expression level of HLJ1
compared with that of TBP was defined as –DCT= –[CTHLJ1–
CTTBP]. The HLJ1/TBP mRNA ratio was calculated as 2
–DCT 6
K, in which K is a constant. Experiments were performed three
times in triplicate.
Transfection and Luciferase Reporter Assays
All transfections were performed in triplicate in 6-well plates,
and the detailed protocol has been described in previous studies
[23], [24]. Briefly, CL1–5 cells were seeded for 24 h prior to
transfection. Plasmids were transfected into cells using Lipofecta-
mine 2000 reagent according to the manufacturer’s instructions
(Invitrogen, Carlsbad, CA, USA). The HLJ1 promoter and
enhancer luciferase reporter constructs [23], [24] and the control
plasmid were cotransfected with a b-galactosidase construct, pSV-
b-Gal (Promega, Madison, WI, USA). All constructs were
confirmed by restriction endonuclease digestion and DNA
sequencing. The ratio of the DNA amounts for luciferase reporter
constructs versus b-galactosidase construct was 3:1. The cells were
incubated in transfection mixture for 4 h and then harvested after
44 h in culture with or without DMSO treatment. An aliquot of
cell lysate (10–25 ml) was used to assay luciferase activity using
a luciferase assay kit (Tropix, Inc., Bedford, MA, USA). Another
aliquot (10–25 ml) was used to measure b-galactosidase activity
using the Galacto-Light chemiluminescent assay kit (Tropix, Inc.).
Luminescence was measured with a Victor 3 multilabel counter
(Perkin-Elmer). Transfection efficiency was normalized with b-
galactosidase activity. Each experiment was repeated at least three
times in duplicate.
Invasion and Migration Assays
The invasiveness of CL1–5 cells treated with various concen-
trations of DMSO was examined with transwell chambers (8-mm
pore size; Corning Costar Corp., Cambridge, MA, USA) and
transwell filters coated with Matrigel (BD Biosciences, Franklin
Lakes, NJ, USA) as described previously [22]. The number of cells
that attached to the lower surface of the polycarbonate filter was
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migratory capability of the CL1–5 cells treated with or without
DMSO was assessed using the wound healing approach as
described previously [22]. The number of cells migrating into the
cell-free zone was determined by counting under a light
microscope. All experiments were performed in triplicate.
siRNA Transient Transfection
Desalted siRNA duplexes were synthesized by Qiagen (Valen-
cia, CA, USA) and were annealed following a standard protocol.
The scramble and JunD siRNAs used in this assay were described
previously [23], [27]. siRNAs were transfected using the RNAiFect
Transfection Reagent (Qiagen) according to the manufacturer’s
instruction. After 24 h, cells were treated with various concentra-
tions of DMSO for another 24 h.
Cell Proliferation and Colony Formation Assay
CL1–5 cells were seeded onto 96-well plates (3 6 10
3 cells/
well). RPMI-1640 complete medium with various concentrations
of DMSO (0–2%) were replaced the next day, beginning the day
after seeding. After culturing for various durations (24, 48, 72,
and 96 h), cell proliferation was evaluated by thiazolyl blue
tetrazolium bromide (MTT) assay according to the manufac-
turer’s protocol (Chemicon). All experiments were performed in
two independent experiments (n = 6 per group). To determine
anchorage-dependent colony formation, CL1–5 cells were seeded
at 200 cells per well in RPMI-1640 complete medium in 6-well
plates. The plates were incubated for 7–10 days and then stained
with 0.1% crystal violet. To determine anchorage-independent
growth, 6-well plates were precoated with 0.7% agarose in
RPMI-1640 with 10% FBS, and CL1–5 cells were seeded at 1.5
6 10
3 cells per well in 0.35% agarose/RPMI-1640 with 10%
FBS. The plates were incubated for 1 month and then stained
with 0.1% crystal violet. Colonies with a diameter greater than
1 mm were counted under an inverted microscope. The colony
formation assays were assessed in two independent experiments
in triplicate.
UV Irradiation and Flow Cytometry
A flow cytometer was employed to determine the percentage
of the sub-G1 cell population, which indicates UV-induced
apoptosis. UV-irradiation was followed mainly as described
previously [26]. Briefly, CL1–5 cells were seeded at a density
of 8610
5 cells/10 cm dish in medium with 10% FBS. After
overnight preincubation at 37uC, cells were pretreated with 1%
or 2% of DMSO for 24 h and then exposed to 10 J/m
2 of UV
irradiation (254 nm) (BIO-LINK BLX-254, Vilber Lourmat,
France). After recovery for 48 h, each sample was washed with
ice-cold PBS, harvested and fixed in 70% (v/v) ethanol for 2 h at
–20uC. Cells were treated with RNaseA and stained with 25 mg/
ml propidium iodine. Samples were analyzed using a Cytomics
TM
FC500 flow cytometer (Beckman Coulter, Brea, CA, USA),
according to the manufacturer’s protocol. Cytometric data were
analyzed with WinMDI 2.8 software. A minimum of 10,000
events were examined. Experiments were performed three times
in duplicate.
Statistical Analysis
All experiments were performed three times in triplicate and
significant differences were analyzed by ANOVA (Excel,
Microsoft). Data were considered statistically significant at P ,
0.05. Where appropriate, results are presented as the means 6
SD.
Results
Cytotoxic Effects of DMSO on CL1–5 Cells
The effects of dimethyl sulfoxide on the viability of CL1–5 cells
are shown in Figure 1. Data presented in Figure 1A indicate a dose
response relationship with respect to the cytotoxicity of DMSO.
On in vitro cultured CL1–5 cells, low and moderate DMSO
treatment did not cause cytotoxicity up to a 2% (v/v)
concentration. However, at the high concentrations of DMSO
($ 5%), approximately 50% or more reduction in cell viability was
observed. The cells became round, shrunk and lost their stress
fibers and normal morphology after 5% DMSO treatment, as
shown in Figure 1B. Thus, we chose the doses no more than 2%
DMSO for further functional assays.
DMSO Stimulates HLJ1 Expression in Various Lung
Adenocarcinoma Cells
To determine whether DMSO induces expression of the tumor
suppressor HLJ1, different lung adenocarcinoma cells were treated
with various doses of DMSO, and then real-time QRT-PCR and/
or Western blot analysis were performed (Figure 2 and Figure S1).
As shown in Figures 2A and 2B, DMSO increased the mRNA and
protein expressions of HLJ1 in CL1–5 cells in a concentration-
dependent manner. HLJ1 expression was induced at DMSO
dosages between 1% and 2%. The HLJ1 expression level was
increased approximately 2- and 4-fold with 1% and 2% DMSO,
respectively. In addition, DMSO also induced HLJ1 protein
expression levels in A549 and H1299 cells below 1% DMSO
dosage in a concentration-dependent manner (Figure S1). Taken
together, these findings indicate that the HLJ1 induction by
DMSO may be a common phenomenon among different lung
adenocarcinoma cell lines. To rule out the possibility that the
induction of HLJ1 was due to solvent stress effect, CL1–5 cells
were treated with various doses of ethanol and the HLJ1
expression levels were determined using Western blot analysis.
As shown in Figure S2, solvent ethanol has no effect on the
induction of HLJ1. The non-cytotoxic 2% DMSO was chosen for
further time course experiments. The results showed that DMSO
induced mRNA and protein expression levels in a time-dependent
manner (Figures 2C and 2D). The HLJ1 mRNA and protein levels
increased after 2 h of DMSO treatment and reached a maximum
level at 6 h (P , 0.05), which was sustained for up to 48 h at the
protein level.
The AP-1 Site within the HLJ1 Enhancer is Responsible for
HLJ1 Induction by DMSO
We have previously determined that the YY1 and AP-1 binding
sites in the HLJ1 promoter and enhancer regions play a major role
in HLJ1 transcriptional regulation [24]. To study whether DMSO
could regulate HLJ1 expression through the promoter and/or
enhancer regions of HLJ1, several constructs with deletions or
mutations were used [24]. The full-length of the HLJ1 promoter
with enhancer (pGL3-FRER’) was used to show that DMSO could
induce luciferase activity in a concentration-dependent manner
(Figure 3A). In addition, the luciferase activity of the HLJ1
promoter was increased more effectively with an intact AP-1 site
(pGL3-F1RER’) than with an AP-1 site deletion (pGL3-F2RER’)
after 2% DMSO treatment (Figure 3B). Moreover, DMSO had
less effect on the full-length construct with the mutated AP-1 site
within the HLJ1 enhancer. When compared with the wild-type
construct (FRER’; AP-1 WT), the mutant of the AP-1 binding site
(AP-1 Mut) significantly reduced HLJ1 full-length promoter
activity to 49% of WT activity after 2% DMSO treatment
(Figure 3C). These results indicate that the AP-1 site is critical for
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rected mutagenesis analysis indicated that DMSO could signifi-
cantly activate HLJ1 enhancer activity through the AP-1 site and
not the SP1 site in CL1–5 cells in a concentration-dependent
manner (P , 0.05; Figure 3D).
There are several protein components that make up the AP-1
complex including c-Jun, c-Fos, JunD, JunB, Fra-1, Fra-2, and
FosB. We have previously shown that JunD and JunB can
upregulate HLJ1 expression [24]. While studying the effects of
DMSO on the AP-1 subfamily, we found that JunD and JunB
were also significantly induced by DMSO in CL1–5 cells
(Figure 4A). However, the expression levels of Fra-1 are not
affected significantly by DMSO over the concentration range
used (0.1–2%). To determine the role of JunD in DMSO-
induced HLJ1 expression, JunD siRNA was transfected into
DMSO-treated CL1–5 cells to knock down JunD expression as
described previously [27]. Figure 4B shows that pretreatment
with JunD siRNA was able to reduce DMSO-induced HLJ1
expression, whereas the scramble siRNA had no effect.
However, the expression level of the transcription factor YY1
was not changed with or without DMSO treatment (data not
shown).
DMSO Inhibits Cancer Cell Migration and Invasion
Through Induction of HLJ1
CL1–5 is a highly invasive cancer cell line both in vitro and
in vivo [29]. In our previous study, we demonstrated that HLJ1
expression levels were markedly lower in CL1–5 cells than in less
invasive cells. Additionally, overexpression of HLJ1 in CL1–5 cells
can inhibit cancer cell invasion and migration [22]. As we
determined that 2% DMSO can induce HLJ1 expression in CL1–
5 cells, we next investigated the effects of 2% DMSO on migration
and invasion by CL1–5 cells in the wound-healing and Matrigel-
based transwell assays. The results revealed that DMSO (1–2%)
significantly inhibits CL1–5 cancer migration in a concentration-
and time-dependent manner (Figures 5A and 5B). We found that
the migration capability of CL1–5 cells was decreased significantly
after HLJ1 induction (6 hr treatment of 2% DMSO) (P , 0.05).
Furthermore, the Matrigel-based transwell assay indicated that
DMSO could also significantly inhibit CL1–5 cell invasion,
especially with 2% DMSO, which induces higher HLJ1
expression (P , 0.05; Figure 5C). In our previous study, we
showed that the reduction in cancer cell invasion is mediated, at
least in part, through upregulation of E-cadherin expression [23].
Thus, we used real-time RT-PCR to examine whether DMSO
treatment could also affect the expression of E-cadherin. The
results showed that the expression of E-cadherin was upregulated
by DMSO; however, Slug expression was down-regulated
(unpublished data).
DMSO Suppresses Cancer Cell Proliferation and Colony
Formation
We next examined whether CL1–5 cancer cell proliferation
activity was affected by DMSO treatment. The results showed that
DMSO can inhibit cancer cell proliferation in a dose-dependent
manner, as shown by MTT assay (Figure 6A). The inhibitory
effects of DMSO on anchorage-dependent and -independent
growth are shown by significantly reduced colony formation of
CL1–5 cells treated with 1% and 2% DMSO compared with no
treatment (P , 0.05; Figures 6B and 6C). Previous data
demonstrated that HLJ1 expression can inhibit lung cancer cell
proliferation and anchorage-independent growth [22], and our
study shows that DMSO can stimulate HLJ1 expression in CL1–5
Figure 1. Effects of various concentrations of DMSO on CL1–5
cell viability. (A) The viability of lung adenocarcinoma CL1–5 cells
cultured with various concentrations of DMSO by MTT assay. *P ,
0.0005, #P , 0.0001 significantly different from the vehicle-treated
control. (B) CL1–5 cells treated with or without DMSO were stained with
phalloidin-tetramethylrhodamine isothiocyanate conjugate to detect F-
actin (red). DMSO-treated cells exhibit fewer filopodia fibers, whereas
the high concentration of DMSO (5%) leads to the cell death. The cell
nuclei were counter stained with DAPI. The image magnification
is6400.
doi:10.1371/journal.pone.0033772.g001
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cell proliferation and colony formation are mediated by induction
of HLJ1.
DMSO Increases UV-induced Apoptosis Through
Enhancing the Expression of HLJ1
Our previous study showed that induced expression of HLJ1 in
CL1–5 cells can promote UV-induced apoptosis through activa-
tion of JNK and caspase-3 [26]. To determine the effects of
DMSO on UV-induced apoptosis, CL1–5 cells were pretreated
with 1% or 2% DMSO and then exposed to UV light. Western
blot analyses showed that UV exposure led to a dramatic decrease
in the HLJ1 expression level, even after DMSO pretreatment,
compared with the non-treated control (Figure 7A). However, the
decrease in HLJ1 was accompanied by increased cleavage of
PARP, an important substrate of caspase-3, in a dose-dependent
manner. In the control group, DMSO treatment increased HLJ1
expression in a dose-dependent manner (Figure 7B; P , 0.05).
After UV exposure, HLJ1 expression increased only with 2%
DMSO pretreatment (Figure 7B; P = 0.014). As shown in
Figure 7C, CL1–5 cells treated with DMSO alone had a slightly
positive change in percent of apoptotic cells, but pretreatment with
DMSO led to a significant increase in the percentage of UV-
induced apoptotic cells compared to that of cells not pretreated
with DMSO (P , 0.05 ).
Discussion
Dimethyl sulfoxide is a by-product of the wood industry that
has been used extensively as a common solvent and pharma-
ceutical agent. It is predominantly used as a topical analgesic
and as a vehicle for drug therapy because of its antioxidant and
anti-inflammatory effects [5–7], [32]. Many reports have
recommended its use in pain, inflammation, interstitial cystitis,
Figure 2. DMSO induces HLJ1 expression in concentration-dependent and time-dependent manners. (A) Real-time quantitative RT-PCR
reveals that HLJ1 mRNA expression was induced by DMSO in a concentration-dependent manner (0.1–2%, v/v) after 48 h incubation.
(B) Concentration-dependent DMSO-induced HLJ1 expression at the protein level was confirmed by Western blot analysis. a-tubulin was a control for
protein loading and transfer. (C) Time-dependent DMSO-induced HLJ1 expression at the mRNA level was verified by real-time quantitative RT-PCR.
The results indicated that the mRNA level of HLJ1 was significantly increased after 2% DMSO treatment for 2 h. *P , 0.05, significantly different from
the vehicle-treated control. (D) The protein expression level of HLJ1 after 2% DMSO treatment at the indicated time was detected by Western blot
analysis. The result indicated that HLJ1 protein expression was time-dependent and was sustained with DMSO treatment for 48 h. a-tubulin was
a control for protein loading and transfer.
doi:10.1371/journal.pone.0033772.g002
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only approved its use for the symptomatic relief of patients with
interstitial cystitis [12]. Some reports have demonstrated the
putative mechanisms or target molecules regulated by DMSO
that mediate its anti-inflammation properties and the ability to
scavenge reactive oxygen species. In addition, it was reported
that DMSO could induce widespread apoptosis at concentra-
tions of 0.5% and 1% in a rat hippocampal culture [35].
However, in our study, cell viability was markedly decreased
with 5% DMSO treatment. Thus, we chose the doses no more
than 2% DMSO for further functional assays.
Recent data reported that DMSO upregulates tumor suppressor
PTEN expression through NF-kB activation in human promye-
locytic leukemic HL60 cells [36]. In this study, our data show that
the expression of another tumor suppressor protein HLJ1 is also
upregulated by DMSO, both at the mRNA and protein levels in
dose- and time-dependent manners. Our previous studies showed
that HLJ1 is regulated by AP-1 through the enhancer region of
Figure 3. Up-regulation of HLJ1 transcriptional activity by DMSO. (A) Relative luciferase activities of pGL3-FRER’ (containing the full-length
HLJ1 promoter and enhancer) were determined in CL1–5 cells treated with various concentrations of DMSO. The results were correlated with the
luciferase activity from cotransfected pSV-b-Gal cells and expressed as relative luciferase activity. *P , 0.05, significantly different from the vehicle-
treated control. (B) 59 deletion constructs of the HLJ1 promoter were represented in the upper panel. Relative luciferase activities of pGL3-F1RER’ and
pGL3-F2RER’ (containing the full-length HLJ1 promoter with or without the AP-1 site, respectively) were determined in CL1–5 cells treated with or
without 2% DMSO. (C) The mutation analysis of the AP-1 site within the HLJ1 minimum enhancer indicated that the AP-1 site is critical for DMSO-
induced HLJ1 promoter activity. *P , 0.05, wild-type AP-1 site constructs compared with mutants. These results are representative of three
independent experiments. (D) Further AP-1 site mutation analysis of the HLJ1 minimum enhancer was confirmed by luciferase assay. The mutant
derivative of the enhancer region where the motif was substituted was fused to the pGL3-promoter vector. Emi-F/APR1, the constructs of site-
directed mutagenesis of the AP-1 site; Emi-SPF/R, the constructs of site-directed mutagenesis of the SP1 site. The results were correlated with the
luciferase activity from cotransfected pSV-b-Gal cells and expressed as relative luciferase activity. *P , 0.05, compared with pGL3-promoter control.
DMSO increases HLJ1 enhancer activity through the AP-1 site in a concentration-dependent manner.
doi:10.1371/journal.pone.0033772.g003
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composed of Jun-Jun and Jun-Fos protein dimers that are involved
in various biological mechanisms including normal cell growth and
tumor development [37]. Chang et al. reported that DMSO,
which serves as an antioxidant, can inhibit sepsis-induced
activation of NF-kB and AP-1, resulting in the suppression of
ICAM-1 gene expression [28]. Indeed, our results confirm that the
AP-1 family members JunD and JunB are upregulated by DMSO
in a dose-dependent manner in lung adenocarcinoma CL1–5 cells.
However, another AP-1 stimulator, phorbol ester, could not
induce the expression levels of JunD and JunB in CL1–5 cells after
24 hr treatment and fail to leading to HLJ1 induction (data not
shown). JunD siRNA significantly but partially blocked this
DMSO-induced HLJ1 expression. As JunB is also enhanced by
DMSO, knockdown of only JunD is not sufficient to block overall
HLJ1 induction. These results are consistent with our previous
study [24]. There are three potential AP-1 binding sites within the
HLJ1 full-length promoter, we could not rule out the possibilities
Figure 4. DMSO induces HLJ1 expression through AP-1. (A)
Western blotting analysis shows that the expressions of the compo-
nents of AP-1 (JunD and JunB) are regulated by DMSO in a dose-
dependent manner, whereas the expression of Fra-1 shows no change
with DMSO treatment. (B) CL1–5 cells transfected with JunD siRNA or
the scrambled siRNA control were treated with or without 2% DMSO for
24 h and then analyzed by Western blotting. Knock-down of JunD
decreased DMSO-induced HLJ1 expression. Data are representative of
at least two independent experiments with b-actin used as the internal
control.
doi:10.1371/journal.pone.0033772.g004
Figure 5. Suppression of in vitro migration and invasion
capabilities of CL1–5 cells by DMSO treatment. (A) DMSO
decreases cancer cell migration ability, as assessed by a scratch wound
healing assay. The track was photographed immediately and after
various times as indicated after wounding. The number of cells that
migrated into the cell-free zone was evaluated (B). The results are
expressed as the total number of the migrated cells. These results are
representative of two independent experiments performed in triplicate.
*P , 0.05, significantly different from the vehicle-treated control at the
indicated time. (C) Invasiveness of CL1–5 cells treated with or without
DMSO was evaluated by the Matrigel-based transwell invasion assay.
Columns, mean derived from three separate experiments done in
triplicate; bars, SD. *P , 0.05, significantly different from the vehicle-
treated control.
doi:10.1371/journal.pone.0033772.g005
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e33772that other AP-1 sites may have some effects on the HLJ1 promoter
activity. In addition, other unknown transcription factors may also
play some roles in this transcriptional regulation. Further studies
will be needed to clarify all of these possibilities mentioned above.
Several mechanisms of the anti-tumor activity of DMSO have
been reported. For example, DMSO has anti-angiogenic effects
via inhibition of MMP-2 production [18], could mimic thalido-
mide to suppress choriocapillary endothelial cell proliferation [38],
and could inhibit vascular smooth muscle cell (VSMC) pro-
liferation and migration [39]. However, this is the first study to
show that DMSO can inhibit lung adenocarcinoma cell migration,
invasion, proliferation, and colony formation through induction of
tumor suppressor HLJ. In recent years, ruthenium-based mole-
cules have emerged as potential antitumor and antimetastatic
agents. For instance, NAMI-A, [ImH][trans-RuCl4(DMSO)(Im)]
(Im=imidazole), a Ru(III) complex with DMSO and imidazole
coordinated to the ruthenium, has finished the phase I study [40].
In acidic environment, the hydrolysis of the ligand DMSO in
NAMI-A may affect its antimetastatic activity [41], [42]. Whether
the antimetastatic effect produced by NAMI-A through DMSO
hydrolysis is mediated by HLJ1 induction needs further in-
vestigation. Furthermore, consistent with our data, a previous
study demonstrated that DMSO-treated murine alveolar carcino-
ma line 1 cells form significantly fewer metastases than parental
cell lines [43]. In contrast, Takenaga reported that treatment of
Lewis lung carcinoma cells (P-29) with DMSO enhanced their
metastatic potential [44]. This result is very different from that of
others and ours; one possible reason is that the reports studied
different cell lines. The different cell contents and genetic
backgrounds may affect the results of these studies.
A previous study observed that DMSO could induce apoptosis
in murine lymphoma cells through mitochondrial dysfunction and
caspase-9 and -3 activation [45]. In addition, a recent report
suggested that DMSO sensitized human myeloid leukemia cells to
death-receptor-mediated apoptosis through mitochondrial mem-
brane depolarization [46]. In our previous study, we demonstrated
that HLJ1 could promote UV-induced apoptosis through
enhancing JNK and caspase-3 activation in NSCLC [26].
Moreover, HLJ1 serves as a novel target of caspase-3 that is
degraded at a late stage of apoptosis. Our data in the present study
also showed that DMSO treatment induced the expression of
HLJ1 and caused marked PARP cleavage after UV exposure,
ultimately leading to increased cancer cell apoptosis. Taken
together, these data suggest that the induction of sensitivity to UV
irradiation by treatment with DMSO is mediated by HLJ1
upregulation in human lung cancer cells. However, whether HLJ1
plays a role in the mitochondrial pathway is still unknown. Further
studies will be needed to clarify the relationship between HLJ1 and
mitochondrial dysfunction in the apoptosis pathway. In addition,
our results suggested that the concentration of DMSO used as the
drug solvent would lead to expression of some genes (0.1%
DMSO, Figure S1) and this issue should be noticed and
considered in the medical therapeutic strategy. We also provide
some clues that appropriate concentration of DMSO used under
lethal dose may synergistically improve the effects of radiotherapy
and chemotherapy in lung cancers.
Figure 6. Inhibition of proliferation and colony formation of
CL1–5 cells by DMSO treatment. (A) The proliferation of CL1–5 cells
treated with various concentrations of DMSO was assessed by MTT
assay (n = 6 per group). #P , 0.05, 0.1–1% DMSO treatment
significantly different from the no-treated control. *P , 0.05, 2% DMSO
treatment significantly different from the no-treated control. (B) DMSO
inhibits the anchorage-dependent colony formation of CL1–5 cells (n =
4 per group). *P , 0.05, significantly different from the no-treated
control. (C) Anchorage-independent colony formation of CL1–5 cells
was determined by soft agar assay (n = 4 per group). DMSO inhibits the
anchorage-independent colony formation of CL1–5 cells. *P , 0.05,
significantly different from the no-treated control.
doi:10.1371/journal.pone.0033772.g006
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e33772In summary, our results suggest that DMSO is an important
stimulator of the tumor suppressor protein HLJ1 through JunB
and JunD activation in the highly invasive lung adenocarcinoma
CL1–5 cells. This study is an important contribution both for the
knowledge of the regulation, function and biomedical relevance of
the tumor suppressor protein HLJ1 and for the understanding of
the biological effects and mechanisms induced by DMSO. Our
results also implied that DMSO may serve as a lead compound or
ligand for the development of anticancer drugs that induce HLJ1
expression and regulate cell migration/invasion and cell pro-
liferation-related pathways. These efforts will help us to develop
not only the novel anti-cancer drugs for lung cancer progression
but also new therapeutic strategies for the disease. For instance,
a therapeutic strategy combining both induced expression of HLJ1
by DMSO-derived analogs and irradiation would synergistically
increase the efficacy of radiotherapy and prolong lung cancer
patient survival.
Supporting Information
Figure S1 DMSO induces HLJ1 expression in different
lung adenocarcinoma cells in concentration-dependent
manners. Concentration-dependent DMSO-induced HLJ1 ex-
pression at the protein level was determined by Western blot
analysis in A549 (A) and H1299 (B) cells. a-tubulin was an internal
control for protein loading and transfer.
(TIF)
Figure S2 Ethanol has no effect on HLJ1 induction in
CL1–5 cells. Western blot analysis reveals that HLJ1 protein
expression was not induced by ethanol under various concentra-
tions tested (0.1–5%, v/v) after 48 h incubation. b-actin was an
internal control for protein loading and transfer.
(TIF)
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